CARDIOVASCULAR RESEARCH SERVICES
TM3 founders are patent holders of technologies that enhance Reverse Cholesterol Transport (RCT)-the Holy Grail for atherosclerosis. Most experts in the field agree that while statins are enormously useful in preventing further atherosclerotic plaque buildup, they do not necessarily promote reversal or removal of plaques already present. Enhancing the body's own reverse cholesterol mechanism would theoretically remove these plaques. This theory was proved during several pre-clinical trials and a phase I clinical trial.
TM3 founders have significant pre-clinical R&D experience using Apo A mimetics, and in vitro assays to measure the extent of RCT of lead compounds. The use of Apo A mimetics in enabling the creation of pre-beta HDL particles is an exciting avenue of R&D.
If your R&D compounds are targeting or enhancing RCT, we have the skills and assays to significantly speed up your process. Remember, our motto is why out-source to India and China and have to worry about your IP, when TM3 can offer you the best pricing in the U.S. and U.S. standards.
Please Contact Us regarding this exciting field.